NCT06173037 2026-01-07
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
Phase 2 Completed
RemeGen Co., Ltd.
Evergreen Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Chinese PLA General Hospital
Hospital Israelita Albert Einstein
Fujian Cancer Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
On Target Laboratories, LLC
Women's Hospital School Of Medicine Zhejiang University
Maastricht Radiation Oncology
Huazhong University of Science and Technology